Watchlist Price Alert

CytomX Therapeutics Inc. (CTMX)

NASDAQ: CTMX · Real-Time Price · USD

2.13

1.20 (129.43%)

At close: May 12, 2025, 3:59 PM

2.22

4.21%

Pre-market: May 13, 2025, 07:36 AM EDT

129.43% (1D)

Bid	2.2
Market Cap	171.75M
Revenue (ttm)	138.1M
Net Income (ttm)	31.87M
EPS (ttm)	0.38
PE Ratio (ttm)	5.61
Forward PE	-1.94
Analyst	Hold

Ask	2.24
Volume	110,248,435
Avg. Volume (20D)	2,060,059
Open	1.90
Previous Close	0.93
Day's Range	1.65 - 2.18
52-Week Range	0.40 - 2.81
Beta	1.10

About CTMX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CTMX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CTMX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

CytomX Therapeutics has released their quartely earnings on May 12, 2025:

Revenue of $50.92M exceeds estimates by $15.5M, with 22.80% YoY growth.

EPS of 0.27 exceeds estimates by 0.14, with 58.82% YoY growth.

Why Price Moved

20 hours ago New

+129.43%

CytomX Therapeutics shares are trading higher. The... Unlock content with Pro Subscription

2 months ago

+7.71%

CytomX Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

News

20 hours ago · seekingalpha.com

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden -...

1 day ago · benzinga.com

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.

15 hours ago · zacks.com

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.

2 weeks ago · zacks.com

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.

2 months ago · zacks.com

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago · zacks.com

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to earnings of $0.01 per share a year a...

2 months ago · seekingalpha.com

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants R...

2 months ago · zacks.com

CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?

On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.